Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ebrasodebart - Enthera

Next Previous
Drug Profile

Ebrasodebart - Enthera

Alternative Names: ENT-001

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ospedale San Raffaele
  • Developer Enthera
  • Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Insulin like growth factor binding protein 3 inhibitors; TMEM219 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases; Type 1 diabetes mellitus

Most Recent Events

  • 26 Sep 2025 Ebrasodebart is still in phase I trials for Inflammatory bowel disease and Type 1 diabetes mellitus (In Volunteers) in Netherlands (IV, Infusion)
  • 15 Sep 2025 Pharmacodynamics data from a preclinical trial in type 1 diabetes presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD-2025)
  • 28 May 2025 Pharmacodynamics data from a preclinical trial in Inflammatory bowel diseases released by Enthera

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top